Call: 860-258-3470

Daniel E. Morganstern, MDContact Info


Hematology / Oncology

Medical School

State University of New York (SUNY); Brooklyn, NY

Internship

New England Deaconess Hospital; Boston, MA

Residency

New England Deaconess Hospital; Boston, MA

Fellowship

Hematology/Oncology fellow: Beth Israel Deaconess Medical Center; Boston, MA
Clinical fellow: Harvard Medical School; Boston, MA
Research fellow: Harvard Medical School; Boston, MA

Board Certification

Board certified in Internal Medicine
Board certified in Medical Oncology
Board certified in Hematology

  • Biography

    Dr. Morganstern is originally from Westchester County, New York. He graduated with a BA from Vassar College in Bioethics. He earned his medical degree from the State University of NY Health Science Center in Brooklyn. He received Phi Beta Kappa and Alpha Omega Alpha honors for his undergraduate work and graduate studies respectively.

    Dr. Morganstern completed his residency at the New England Deaconess Hospital in Boston. He then completed a fellowship in Hematology and Oncology at the Beth Israel Deaconess Medical Center in Boston.

    Dr. Morganstern has been a medical oncologist since 1997. He practiced as a general oncologist at the Lahey Clinic until 2004. He was then recruited to work at the Dana-Farber Cancer Institute as a Breast Oncology subspecialist where he worked in the Susan F. Smith Center for Women’s Cancers from 2004 to 2018.  During this time he also served as the Clinical Lead for the Women’s Cancer Program inpatient services at Brigham and Women’s Hospital.

    Dr. Morganstern has been the site principal investigator of Phase II and Phase III trials in breast cancer at Dana-Farber Cancer Institute. In addition to his expertise in breast oncology, Dr. Morganstern has major interest and experience in the area of clinical breast/ovarian cancer genetics, risk models to predict the risk of breast cancer in unaffected women, and management of women at increased risk for breast cancer by virtue of family history, mammographic density, and risk lesions such as atypical hyperplasia. In this regard Dr. Morganstern co-directed the Breast Cancer Personalized Risk Assessment and Prevention Center at Brigham and Women’s Hospital.

    Dr. Morganstern’s approach to breast cancer in this age of personalized medicine recognizes that every woman’s treatment plan is necessarily unique. He believes in meeting patients where they are in terms of their knowledge, lifestyle, and psychological state. He works with each patient as an individual and places a strong emphasis on education and empowering women so they can make informed decisions.

    He is pleased to move to the Greater Hartford area and looks forward to being part of a practice that takes a personalized and collaborative approach to patient care.

  • Media

    Dr. Morganstern is featured on Fox TV where he discusses a major research finding that indicates that chemotherapy may no longer be beneficial to treat certain types of breast cancer.

  • Clinical Interests

    Dr. Morganstern has been the site principal investigator of Phase II and Phase III trials in breast cancer at Dana Farber Cancer Institute. In addition to his expertise in breast oncology, Dr. Morganstern has major interest and experience in the area of clinical breast/ovarian cancer genetics, risk models to predict the risk of breast cancer in unaffected women, and management of women at increased risk for breast cancer by virtue of family history, mammography density, and risk lesions such as atypical hyperplasia.

  • Commendations

    Instructor in medicine at Harvard Medical School and teacher to medical students, residents and fellows, 2004-2018
    Lecturer at regional continuing medical education programs and presenter at national meetings such as ASCO and MASCC
    Named Boston Top Doctor in Oncology in Boston Magazine, 2017

  • Professional Organizations

    Active member of the American Society of Clinical Oncology